Targeting Pupil Size for Presbyopia Management

Andrew S. Morgenstern, OD, FAAO, FNAP, highlights the importance of reducing pupil size to a certain level to optimize near vision for patients with presbyopia.

Using Miotic Agents for the Management of Presbyopia

Expert eye care specialists discuss the role of miotic agents in targeting presbyopia in patients.

Impact of Presbyopia on Mechanism of Ocular Accommodation

Drs Andrew S. Morgenstern and Francis S. Mah provide insight on the functionality of ocular accommodation as an autofocus lens and how this is affected in patients with presbyopia.

Overview of Presbyopia

November 23, 2022

Francis S. Mah, MD, and Andrew S. Morgenstern, OD, FAAO, FNAP, review the impact of presbyopia on quality of life as well as current treatment options and unmet needs for disease management.

Visus Therapeutics CEO announces acquisition of ViewPoint Therapeutics to expand on cataract, presbyopia candidate

September 30, 2022

Ben Bergo, CEO of Visus Therapeutics, announced the acquisition of all patents and other assets of ViewPoint Therapeutics, which will accelerate development of novel alpha-crystallin chaperone compounds as a non-surgical treatment for age-related cataracts.

VIDEO: Drops for presbyopia correction show promise in Phase 3 safety studies

September 20, 2022

At the recent Women in Ophthalmology Summer Symposium, held in Monterey, California, Cathleen M. McCabe, MD, outlined how pilocarpine HCl Ophthalmic Solution 1.25%, the first and only FDA-approved eye drop to treat presbyopia could offer an opportunity for patients looking for spectacle independence.